patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Back To Forum List View

emit

Rank: Vice President [?]

Points: 41186 [?]

Votes: 199 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

sweet

posted on Sep 16, 2013 12:24PM

Pluristem Therapeutics Inc. (NASDAQ: PSTI) upgraded to Buy with price target $8 by Maxim Group

Monday, Sep 16, 2013 10:25 AM ET by Betsy O'Brien Harrison

Maxim Group upgraded Pluristem Therapeutics Inc. (NASDAQ: PSTI) to Buy with price target $8. Previously Maxim Group upgraded

to Pluristem Therapeutics Inc. (NASDAQ: PSTI) to Hold on 06/04/2013, when the stock price was $2.92. Since then, Pluristem Therapeutics Inc.'s stock price has gained 18% as of 09/16/2013's recent price of $3.45.

1 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply